Probably involves the following mechanisms: (1) direct tumor-mediated bone destruction through receptor activator of NF-κB ligand/osteoprotegerin axis dysregulation, increasing osteoclast activity and (2) treatment-induced skeletal damage, where Chemotherapy can be affected on physiological function of movement system and the skeleton construction. The gene discussed is TNFRSF11B; the disease is neoplasm.